Skip to main content

Table 3 The results of univariate and multivariate Cox proportional hazard analysis in this study

From: Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics

Variable

Univariate cox regression

Multivariate cox regression

P-value*

Hazard ratio (95% confidence interval)

P-value*

Hazard ratio (95% confidence interval)

Age

0.633

0.99(0.98, 1.02)

  

Gender

   

 Male

0.637

0.75 (0.23, 2.43)

 Female

  

Smoking

   

 No

  

 Yes

0.775

0.93 (0.57,1.53)

Drinking

   

 No

  

 Yes

0.691

1.11(0.67, 1.83)

Ascites

    

 No

    

 Yes

0.0148

1.99(1.14, 3.46)

0.0446

1.86 (1.02, 3.41)

BMI

0.001

0.84 (0.76,0.93)

0.0173

0.87(0.77, 0.98)

Chronic hepatitis

   

 No

  

 Yes

0.144

0.46(0.16, 1.30)

Liver cirrhosis

   

 No

  

 Yes

0.89

1.04 (0.58, 1.87)

AFP a

0.0004

1.16 (1.07, 1.26)

0.021

1.10 (1.02, 1.20)

ALT

0.731

1.00 (0.99, 1.005)

  

AST

0.0428

1.00 (1, 1.007)

0.68

0.999(0.994, 1.00)

ALB

    

 ≤ 37.5

0.003

2.18 (1.30, 3.66)

0.0103

2.16 (1.20, 3.90)

 > 37.5

    

GGT

0.191

1.00 (0.99, 1.001)

  

TBIL

0.125

1.02(1.00, 1.04)

  

DBIL

0.025

1.05(1.01, 1.09)

0.52

1.02(0.96, 1.08)

PLT

0.112

1.00 (0.99, 1.01)

  

LYM

0.919

1.02 (0.66, 1.60)

  

PT

0.0793

1.17(0.98, 1.39)

  

INR

0.0263

6.01(1.24, 29.21)

0.061

6.11(0.92, 40.62)

Child-Pugh class

    

 A

    

 B

0.0002

3.65(1.85, 7.19)

0.46

0.66(0.21, 2.01)

BCLC stage

   

 A

  

 B

0.542

1.36(0.50, 3.69)

 C

0.334

1.58(0.62, 4.03)

ALBI grade

   

 1

  

 2

0.072

1.69(0.95, 2.98)

 3

0.094

3.59(0.80, 16.01)

TNM Classification

   

 II

  

 III

0.37

1.56(0.59, 4.14)

 IV

0.252

1.65(0.70, 3.89)

Tumor size

    

 ≤ 5.0

0.017

0.53 (0.30, 0.89)

0.004

0.40 (0.21, 0.74)

 >5

    

Tumor number

    

 Solitary

    

 Multiple

0.015

1.863(1.13, 3.08)

0.081

1.614(0.94, 2.77)

Portal vein invasion

    

 No

    

 Yes

0.013

1.865(1.14, 3.06)

0.465

1.228(0.71, 2.13)

  1. a The value is the natural logarithm of clinical alpha-fetoprotein
  2. P-value* < 0.05 indicates a significant difference between the training and validation cohorts
  3. Abbreviations: BMI, Body Mass Index; AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; GGT, glutamyl transpeptidase; TBIL, total bilirubin; DBIL, Direct Bilirubin; PLT, platelet count; LYM, lymphocyte; PT, prothrombin time; INR, international normalized ratio; BCLC, Barcelona Clinic Liver Cancer; ALBI, albumin-bilirubin; TNM, Tumor Node Metastasis
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us